OncoMatch/Clinical Trials/NCT06942416
Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer
Is NCT06942416 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Paclitaxel and Cisplatin/ Carboplatin and Iparomlimab and Tuvonralimab for cervical cancer.
Treatment: Paclitaxel and Cisplatin/ Carboplatin · Iparomlimab and Tuvonralimab — The goal of this clinical trial is to evaluation the efficacy and safety of iparomlimab and tuvonralimab, paclitaxel + cisplatin/carboplatin combined with radiotherapy of locally recurrent and oligometastatic cervical cancer.The main questions it aims to answer are: 1. Does the combination therapy improve the overall response rate (ORR), progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and safety in participants? 2. What are the predictive biomarkers of treatment efficacy, and how can this information better guide the use of immune-oncology drugs in combination therapy? Participants will: * Receive iparomlimab and tuvonralimab, Paclitaxel + Cisplatin/Carboplatin and radiation therapy according to a specified protocol. * Visit the clinic for regular checkups and tests throughout the treatment period. * Be monitored for and have records kept of ORR, PFS, DCR, OS, and safety. * Provide hematologic、tissue and stool samples to explore biomarkers. This study will help determine if this combination therapy can become a new standard of care for patients with locally recurrent and oligometastatic cervical cancer as well as identify biomarkers to better guide treatment strategies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immunotherapy
Prior immunotherapy (e.g., immune checkpoint inhibitors)
Cannot have received: radiotherapy
Prior radiotherapy...completed <4 weeks before study treatment (or <5 drug half-lives, whichever is longer)
Cannot have received: chemotherapy
Prior...chemotherapy...completed <4 weeks before study treatment (or <5 drug half-lives, whichever is longer)
Cannot have received: hormonal therapy
Prior...hormonal therapy...completed <4 weeks before study treatment (or <5 drug half-lives, whichever is longer)
Cannot have received: surgery
Prior...surgery...completed <4 weeks before study treatment (or <5 drug half-lives, whichever is longer)
Cannot have received: targeted therapy
Prior...targeted therapy...completed <4 weeks before study treatment (or <5 drug half-lives, whichever is longer)
Lab requirements
Blood counts
hemoglobin (hb) ≥80 g/l; absolute neutrophil count (anc) ≥1.5×10⁹/l; platelets (plt) ≥50×10⁹/l
Kidney function
serum cr ≤1.5×uln (if >1.5×uln, crcl ≥50 ml/min by cockcroft-gault formula)
Liver function
alt/ast ≤2.5×uln, total bilirubin ≤1.5×uln, alp ≤3×uln, albumin ≥30 g/l
Cardiac function
lvef >50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify